Iterum Therapeutics PLC (NASDAQ:ITRM) — Market Cap & Net Worth
Market Cap & Net Worth: Iterum Therapeutics PLC (ITRM)
Iterum Therapeutics PLC (NASDAQ:ITRM) has a market capitalization of $3.20 Million ($3.20 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29450 globally and #6014 in its home market, demonstrating a 9.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Iterum Therapeutics PLC's stock price $0.06 by its total outstanding shares 53291578 (53.29 Million). Also see Iterum Therapeutics PLC total assets for a full breakdown of the balance sheet.
Iterum Therapeutics PLC Market Cap History: 2018 to 2026
Iterum Therapeutics PLC's market capitalization history from 2018 to 2026. Data shows change from $4.00 Billion to $3.20 Million (-63.42% CAGR). Also see cash efficiency ratio of Iterum Therapeutics PLC for how efficiently the company converts equity into cash flow.
Index Memberships
Iterum Therapeutics PLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #858 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2742 of 3165 |
Weight: Iterum Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Iterum Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Iterum Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ITRM stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
97221.12x
Iterum Therapeutics PLC's market cap is 97221.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $4.00 Billion | $869.00K | -$77.06 Million | 4608.59x | N/A |
| 2019 | $3.60 Billion | $37.00K | -$103.13 Million | 97221.12x | N/A |
Competitor Companies of ITRM by Market Capitalization
Companies near Iterum Therapeutics PLC in the global market cap rankings as of September 18, 2026. Review how tangible is Iterum Therapeutics PLC's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Iterum Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Iterum Therapeutics PLC Historical Marketcap From 2018 to 2026
Between 2018 and today, Iterum Therapeutics PLC's market cap moved from $4.00 Billion to $ 3.20 Million, with a yearly change of -63.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.20 Million | -82.06% |
| 2025 | $17.85 Million | -81.07% |
| 2024 | $94.33 Million | -10.15% |
| 2023 | $104.98 Million | +134.52% |
| 2022 | $44.76 Million | -85.71% |
| 2021 | $313.19 Million | -60.38% |
| 2020 | $790.58 Million | -78.02% |
| 2019 | $3.60 Billion | -10.18% |
| 2018 | $4.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Iterum Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.20 Million USD |
| MoneyControl | $3.20 Million USD |
| MarketWatch | $3.20 Million USD |
| marketcap.company | $3.20 Million USD |
| Reuters | $3.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more